x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

Decera Clinical Education Oncology Podcast

Decera Clinical Education

Updates on new data and best practices in the care of patients with cancer across a wide variety of solid tumors and hematologic malignancies from Decera Clinical Education. Gain practical clinical insights and strategies and earn CME/CE credit for selected episodes.

education courses

All Episodes

00:18:07

Targeted Treatment Options for Patients With AML and...

Decera Clinical Education Oncology Podcast ·

2022/01/10

In this podcast episode, Sarah M. Tinsley, PhD, APRN, AOCN, discusses targeted therapy with FLT3 and IDH1/2 inhibitors in AML, with a focus on the nursing perspective. Topics include:Approved and emerging treatment options for FLT3-mutated AMLManagement of adverse events associated with FLT3 inhibitorsTherapies for IDH1- and IDH2-mutated AMLIdentifying and managing differentiation syndrome associated with IDH1/2 inhibitorsPresenters:Sarah M. Tinsley, PhD, APRN, AOCNNurse PractitionerCourtesy

en

00:13:07

An Overview of AML and Treatment Strategies for...

Decera Clinical Education Oncology Podcast ·

2022/01/10

In this podcast episode, Ashley Leak Bryant, PhD, RN, OCN, FAAN, discusses acute myeloid leukemia and management approaches for patients unfit for intensive chemotherapy, with a focus on the nursing perspective. Topics include:An overview of AMLIdentifying patients unfit for intensive therapyTreatment options for unfit patients including venetoclax combinationsAdverse event profiles of treatment optionsNursing considerations for managing patients with AML unfit for intensive therapyPresenters:Ashley

en

00:11:46

Managing Lower-Risk Myelodysplastic Syndrome: Nursing...

Decera Clinical Education Oncology Podcast ·

2021/12/22

In this podcast episode, Ashley Leak Bryant, PhD, RN, OCN, FAAN, discusses management strategies for lower-risk myelodysplastic syndrome (MDS) with a focus on the nursing perspective. Topics includeRisk scoring and treatment algorithmsCurrent and ongoing clinical trials in the lower-risk MDS settingAdverse event profiles of current treatment optionsNursing considerations for managing a patient with lower-risk MDSPresenters:Ashley Leak Bryant, PhD, RN, OCN, FAANAssociate ProfessorSchool of

en

00:13:09

Managing Higher-Risk and Relapsed/Refractory...

Decera Clinical Education Oncology Podcast ·

2021/12/22

In this podcast episode,Sarah Tinsley, PhD, APRN, AOCN, discusses management strategies for higher-risk and relapsed/refractory (R/R) myelodysplastic syndromes (MDS) with a focus on the nursing perspective. Topics include:Current and ongoing clinical trials in the higher-risk and R/R MDS settingTherapies surrounding transplantNursing considerations for managing a patient with higher risk and/or R/R MDSPresenters:Sarah Tinsley, PhD, APRN, AOCNNurse PractitionerCourtesy Assistant ProfessorDepartment

en

00:12:51

Key Factors Influencing Later-Line Treatment...

Decera Clinical Education Oncology Podcast ·

2021/12/17

In this episode, Chiara Cremolini, MD, PhD, and Teresa Macarulla, MD, PhD, discuss the clinical data that inform how they select regorafenib and TAS-102 as later-line treatment for patients with mCRC, with topics including:Transitioning from second- to third-line therapyFactors in selecting among available therapiesKey predictors of improved outcomes with regorafenib vs TAS-102Presenters:Chiara Cremolini, MD, PhDMedical Oncologist Unit of Medical Oncology 2 Azienda Ospedaliero-Universitaria

en

00:13:18

The Evolving Role of TKIs in First-line Treatment of...

Decera Clinical Education Oncology Podcast ·

2021/12/14

In this podcast episode from Clinical Care Options (CCO), Josep M. Llovet, MD, PhD, and Markus Peck-Radosavljevic, MD, MBA, discuss first-line treatment of patients with advanced hepatocellular carcinoma. Topics include:Atezolizumab plus bevacizumab as the current standard of careContraindications to atezolizumab plus bevacizumabThe current role of tyrosine kinase inhibitors in first-line treatment of advanced hepatocellular carcinomaOngoing clinical trials in the first-line settingPresenters:

en

00:21:08

Expert Insight on Important Clinical Trial Data From...

Decera Clinical Education Oncology Podcast ·

2021/11/23

In this episode, Nicole Concin, MD, PhD, highlights key data for endometrial and ovarian cancers presented at the ESGO 2021 annual meeting, including:Pooled data from 7 phase III clinical trials evaluating surgical outcomes as prognostic factors for patients with high-grade serous, low-grade serous, mucinous, and clear cell ovarian cancerUpdate from the phase I GARNET study in patients with advanced/recurrent mismatch repair deficient/microsatellite instability‒high or proficient/stable endometrial

en

00:15:40

Experts Answer FAQs on Immunotherapy for...

Decera Clinical Education Oncology Podcast ·

2021/11/23

In this podcast episode, Julie Brahmer, MD, MSc, and Jarushka Naidoo, MB BCH BAO, MHS, answer audience questions from a live CCO webinar on evolving immunotherapy strategies for NSCLC, with topics including:Patient and/or disease-related factors considered when choosing first-line immunotherapy-based regimensSecond-line therapeutic options after disease progression on an immunotherapy-based regimenImmunotherapy in patients with advanced NSCLC and brain metastasesDistinguishing between

en

00:13:33

Overcoming Acquired Resistance With Second-Generation...

Decera Clinical Education Oncology Podcast ·

2021/11/09

In this podcast episode, George D. Demetri, MD, and Alexander Drilon, MD, discuss emerging data on the efficacy, safety, and clinical role of second-generation TRK inhibitors that can overcome acquired resistance to first-generation agents in NTRK fusion–positive solid tumors. Topics include:Mechanisms of acquired resistance to TRK inhibitor therapyClinical trial data on the second-generation inhibitors selitrectinib and repotrectinibSafety profiles of first- vs second-generation TRK

en

00:18:15

Role of TKIs in Nonadipocytic Soft Tissue Sarcoma and...

Decera Clinical Education Oncology Podcast ·

2021/11/02

In this podcast episode, Jean-Yves Blay, MD, PhD, and Robin L. Jones, BSc, MBBS, MRCP, MD(Res), discuss the most important clinical trial data on leveraging TKIs as monotherapy and in combination with chemotherapy or immune checkpoint inhibitors for treatment of soft tissue sarcoma and osteosarcoma.Presenters:Jean-Yves Blay, MD, PhDProfessor of Medical OncologyDepartment of MedicineCentre Leon BerardLyon, FranceRobin L. Jones, BSc, MBBS, MRCP, MD(Res)ProfessorSarcoma UnitRoyal Marsden Hospital and

en

00:19:52

PARP Inhibitors in Pancreatic Cancer: Experts Discuss...

Decera Clinical Education Oncology Podcast ·

2021/10/26

In this episode, Philip Agop Philip, MD, PhD, FRCP, and Elena Gabriela Chiorean, MD, discuss the importance of testing for biomarkers along with thecurrent paradigm of PARP inhibitor therapy in the treatment of pancreatic cancer. Topics include:Importance of germline and somatic testingAdverse events associated with PARP inhibitorsMaintenance therapy in pancreatic cancerPresenters:Philip Agop Philip, MD, PhD, FRCPProfessorSchool of MedicineWayne State UniversityLeader, Gastrointestinal

en

00:15:59

Optimal Dosing Strategies With Regorafenib and...

Decera Clinical Education Oncology Podcast ·

2021/10/21

In this episode, Kanwal Raghav, MD, and Rachel Riechelmann, MD, PhD, discuss key data supporting contemporary dosing strategies with the later-line treatment options regorafenib and TAS-102 for patients with mCRC, with topics including:Individualizing therapyClinical data and experience informing optimal dosingKey adverse eventsPresenters:Kanwal Raghav, MD, MBBSAssociate Professor, Gastrointestinal Medical Oncology The University of Texas MD Anderson Cancer CenterHouston, TexasRachel Riechelmann,

en

00:14:09

First-Generation TRK Inhibitors: Clinical Evidence...

Decera Clinical Education Oncology Podcast ·

2021/10/15

In this episode, George D. Demetri, MD, and Alexander Drilon, MD, discuss key clinical data leading to FDA approvals and current indications for first-generation TRK inhibitors in NTRK fusion–positive solid tumors and ROS1-positive NSCLC. Topics include:Basket trials leading to FDA approvals of larotrectinib and entrectinibCurrent pan-tumor indications for first-generation TRK inhibitors in NTRK fusion–positive solid tumors as well as ROS1-positive NSCLCSequencing treatment with TRK inhibition in

en

00:13:53

PARP Inhibitors in Ovarian Cancer: Experts Discuss...

Decera Clinical Education Oncology Podcast ·

2021/10/14

In this episode, Nicoletta Colombo, MD; Philipp Harter, MD, PhD; and Alexandra Leary, MD, PhD, discuss patient cases from a live webinar on the current paradigm and long-term benefits of PARPi therapy in the treatment of ovarian cancer. Topics include:Maintenance therapy in ovarian cancerSOLO1, PRIMA, PAOLO-1 clinical dataRole of bevacizumab in treatment of ovarian cancerPresenters:Nicoletta Colombo, MDProfessor of Obstetrics and GynecologyUniversity of Milan-BicoccaEuropean Institute of

en

00:14:07

Counseling Patients and Caregivers on Prophylaxis...

Decera Clinical Education Oncology Podcast ·

2021/10/08

In this episode, listen to Guy A. Young, MD, as he counsels a teenage patient with severe hemophilia A and the patient’s mother on various available treatment options and strategies for optimizing hemophilia A prophylaxis and adherence. Topics include:Overcoming challenges to adherenceChoice of standard vs extended half-life factor VIII vs emicizumabSafety and efficacy data with emicizumabPresenter:Guy A. Young, MDProfessor of PediatricsDirector, Hemostasis and Thrombosis CenterChildren’s Hospital

en

00:17:13

Rationale for NTRK Testing in Patients With Cancer

Decera Clinical Education Oncology Podcast ·

2021/10/08

In this episode, George D. Demetri, MD, and Alexander Drilon, MD, discuss the biologic rationale behind testing for NTRK fusions in patients with various solid tumors, along with clinical strategies for testing. Topics include:Differences between NTRK fusions vs gene mutationsFrequency of NTRK fusions by age and tumor typeWhen to test patients for NTRK fusions and interpreting reportsMethods of testing: multiplex gene testing, next-generation sequencing of DNA vs RNA, immunohistochemistry, and

en

00:19:25

Expert Answers to HCP Questions on Androgen...

Decera Clinical Education Oncology Podcast ·

2021/10/07

In this episode, Daniel W. Lin, MD; Alicia K. Morgans, MD, MPH; and David F. Penson, MD, answer audience questions from a live CCO webinar focused on current best practices and emerging strategies in androgen deprivation therapy, with questions including:How to select between GnRH agonists and antagonists for initial androgen deprivation therapy?How should androgen receptor inhibitors be incorporated into treatment paradigms for nonmetastatic castration-resistant prostate cancer and metastatic

en

00:23:18

Expert Insight on Important Clinical Trial Data From...

Decera Clinical Education Oncology Podcast ·

2021/09/29

In this episode, Prof. Isabelle Ray-Coquard, MD, PhD, and Bernard Doger de Spéville, MD, PhD, provide expert insights on key new data from ESMO 2021 presented for endometrial and ovarian cancers including:Data from the phase III OReO/ENGOT Ov-38 trial of olaparib rechallenge in patients with recurrent ovarian cancer previously treated with a PARP inhibitor A subgroup analysis of KEYNOTE-775, comparing lenvatinib vs pembrolizumab vs TPC, with outcomes by tumor histology and prior lines of therapyA

en

00:36:31

Expert Insight on New Evidence Poised to Change the...

Decera Clinical Education Oncology Podcast ·

2021/09/28

In this podcast episode, Jeffrey S. Weber, MD, PhD; Allison Betof Warner, MD, PhD; and Hussein Tawbi, MD, PhD, discuss recent key data on adjuvant and neoadjuvant therapy and review the latest evidence on therapies for metastatic disease.Link to full program:https://bit.ly/3ogPjMoFollow along with the downloadable slideset:https://bit.ly/2XYNIztPresenters: Jeffrey S. Weber, MD, PhDDeputy DirectorLaura and Isaac Perlmutter Cancer CenterNYU Langone HealthProfessor of MedicineNYU Grossman School of

en

00:24:37

Expert Insight on Practice Changing From IGCS 2021...

Decera Clinical Education Oncology Podcast ·

2021/09/21

In this episode, Domenica Lorusso, MD, PhD, and Alexandra Leary, MD, PhD, provide expert insights on practice changing data from IGCS 2021 presented for endometrial, ovarian, and cervical cancers regarding:A subgroup analysis from phase III KEYNOTE-775 evaluating lenvatinib plus pembrolizumab efficacy in patients with advanced endometrial cancer and dMMR statusA subgroup analysis from the phase I GARNET trial─cohorts A1 and A2─in patients with advanced endometrial cancer who had received either 1 or

en

224 results

Similar Podcasts

Science Talk

Albert Einstein College of Medicine

五分钟心理学

柠檬心理

Daily Facts

Amalia Dupray and Montgomery Jones.

Les dents et dodo

BFMTV

Veterinary Clinical Podcasts

The Royal Veterinary College